UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017882
Receipt number R000020717
Scientific Title Prospective, randomized, double-blind, placebo-controlled trial in nutritional support for autologous PBSCT Non-synbiotics vs synbiotics
Date of disclosure of the study information 2015/06/12
Last modified on 2021/12/10 15:25:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective, randomized, double-blind, placebo-controlled trial in nutritional support for autologous PBSCT
Non-synbiotics vs synbiotics

Acronym

Prospective, randomized, double-blind, placebo-controlled trial in nutritional support for autologous PBSCT
Non-synbiotics vs synbiotics

Scientific Title

Prospective, randomized, double-blind, placebo-controlled trial in nutritional support for autologous PBSCT
Non-synbiotics vs synbiotics

Scientific Title:Acronym

Prospective, randomized, double-blind, placebo-controlled trial in nutritional support for autologous PBSCT
Non-synbiotics vs synbiotics

Region

Japan


Condition

Condition

malignant lymphoma

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety to use Gfine in patients who receive autologous PBSCT

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Duration of TPN

Key secondary outcomes

(1) Diarrhea and infectious diseases
(2) Regimen related toxicity except diarrhea and infectious diseases
(3) Engraftment
(4) Effect of appetite hormone
(5) Quality of life
(6) GLP-2 blood level
(7) Nutritional condition
(8) Length of stay and Cost-effectiveness
(9) Period of failure to TPN administer


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Synbiotics: Use of Gfine in patients who receive autologous PBSCT

Interventions/Control_2

Placebo: Use of Placebo in patients who receive autologous PBSCT

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Malignant lymphoma who can be candidate for autologous PBSCT
(2) 17<Age<66
(3) ECOG PS <2
(4) No obvious organ failure
(5) They have given written informed consent
(6) Patients who will survive more than 3 months

Key exclusion criteria

(1) History of stem cell transplantation
(2) HIV carrier
(3) Uncontrolled active infectious diseases
(4) Pregnant or lactating
(5) Uncontrolled psychological disorder
(6) Allergy for the drugs used for the conditioning regimen
(7) Allergy for Gfine
(8) Patients who do not tolerate the maximal defined conditioning regimen due to organ dysfunction (e.g., reduce MCNU due to pulmonary dysfunction, reduce Carboplatin due to renal dysfunction)
(9) Patients who do not ingest enough calories
(10) Investigator rejection

Target sample size

12


Research contact person

Name of lead principal investigator

1st name Hironobu
Middle name
Last name Minami

Organization

Department of Medicine, Kobe University Hospital and Graduate School of Medicine

Division name

Medical Oncology/Hematology

Zip code

650-0017

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

TEL

0783825111

Email

hminami@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name Yu
Middle name
Last name Mizutani

Organization

Kobe University Hospital

Division name

Medical Oncology/Hematology

Zip code

650-0017

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

TEL

0783825111

Homepage URL


Email

mizuyu@med.kobe-u.ac.jp


Sponsor or person

Institute

Department of Medicine, Kobe University Hospital and Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Medical Oncology/Hematology, Department of Medicine
Kobe University Hospital and Graduate School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe University Clinical Research Ethical Committee

Address

7-5-2, Kusunoki-cho, Chuo-ku, Kobe city, Hyogo Prefecture, JAPAN, 650-0017

Tel

078-382-6669

Email

cerb@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

12

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 04 Month 19 Day

Date of IRB

2018 Year 12 Month 03 Day

Anticipated trial start date

2015 Year 08 Month 10 Day

Last follow-up date

2020 Year 11 Month 09 Day

Date of closure to data entry

2020 Year 12 Month 04 Day

Date trial data considered complete

2020 Year 12 Month 04 Day

Date analysis concluded

2021 Year 12 Month 10 Day


Other

Other related information



Management information

Registered date

2015 Year 06 Month 11 Day

Last modified on

2021 Year 12 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020717


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name